公司資料
TuHURA Biosciences 股價、新聞與催化劑
- 股票代碼:
- HURA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.36 USD (-0.73%)
收盤價
最後更新: 2026年11月19日
—
市值
股價為何變動
截至 2026年11月19日,HURA 下跌 0.73%,收於 $1.36。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Kintara Therapeutics was an oncology company focused on developing treatments for hard-to-treat cancers before becoming a historical ticker. Its story revolved around small-cap cancer drug development and the search for a viable late-stage asset.
所在地與產業分類
Kintara was headquartered in the United States and listed on NASDAQ. It sat in small-cap oncology biotechnology.
商業模式特徵
The company depended on clinical progress, financing, and strategic focus while advancing a narrow pipeline. Investors historically watched trial updates and capital runway.
生技產業定位
Kintara is best viewed as a historical oncology biotech name. It belonged to the class of small-cap developers where a single program could dominate the story.
未來催化劑
- Kintara is a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. There is no live standalone pipeline story left.
近期新聞
新聞標題由機器翻譯,詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。
